24-Apr-2024
No headlines found.
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to 275 Million
PRNewswire (Thu, 25-Apr 6:00 AM ET)
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
PRNewswire (Tue, 23-Apr 8:09 AM ET)
Opill and WNBA Team Up for Groundbreaking Partnership
PRNewswire (Tue, 9-Apr 12:30 PM ET)
PRNewswire (Mon, 4-Mar 8:00 AM ET)
Perrigo to Attend UBS Global Consumer and Retail Conference
PRNewswire (Thu, 29-Feb 4:21 PM ET)
PRNewswire (Tue, 27-Feb 6:30 AM ET)
Perrigo Increases its Quarterly Dividend
PRNewswire (Mon, 26-Feb 4:30 PM ET)
Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024
PRNewswire (Tue, 13-Feb 8:16 AM ET)
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Perrigo Company PLC trades on the NYSE stock market under the symbol PRGO.
As of April 24, 2024, PRGO stock price climbed to $31.23 with 921,399 million shares trading.
PRGO has a beta of 0.70, meaning it tends to be less sensitive to market movements. PRGO has a correlation of 0.05 to the broad based SPY ETF.
PRGO has a market cap of $4.23 billion. This is considered a Mid Cap stock.
Last quarter Perrigo Company PLC reported $1 billion in Revenue and $.86 earnings per share. This fell short of revenue expectation by $-23 million and exceeded earnings estimates by $.03.
In the last 3 years, PRGO stock traded as high as $50.90 and as low as $25.77.
The top ETF exchange traded funds that PRGO belongs to (by Net Assets): VTI, IJH, VB, VBR, VXF.
PRGO has underperformed the market in the last year with a return of -10.4%, while the SPY ETF gained +24.1%. In the last 3 month period, PRGO fell short of the market, returning -4.6%, while SPY returned +4.5%. However, in the most recent 2 weeks PRGO has outperformed the stock market by returning -1.0%, while SPY returned -1.7%.
PRGO support price is $29.94 and resistance is $31.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRGO stock will trade within this expected range on the day.